Copyright © 1998 by the European Society of Cardiology.
A placebo-controlled study of growth hormone in patients with congestive heart failure
a Research Center for Endocrinology and Metabolism, Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg, Sweden
b Department of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden
c Department of Clinical Physiology, Sahlgrenska University Hospital, Göteborg, Sweden
accepted April 29, 1998
Aim
Experimental data in heart failure models and an open trial of seven patients with idiopathic dilated cardiomyo-pathy have suggested beneficial effects of growth hormone on cardiac function. The aim of the present study was to evaluate growth hormone effects on cardiac function in a placebo-controlled study.
Methods
Twenty two patients with congestive heart failure of different aetiologies in NYHA II and III and an echocardiographic ejection fraction <0·45 were studied in a 3 month double-blind placebo-controlled study with growth hormone added to optimal heart failure therapy. Patients received either placebo (n=11) or recombinant human growth hormone (n=11) in an initial dose of 0·1IU.kg–1week–1for 1 week, and thereafter 0·25IU.kg–1week–1for the rest of the treatment period. Cardiac function was assessed by equilibrium radionuclide angiography and Doppler echocardiography. Functional capacity was evaluated by computerized bicycle exercise electrocardiography.
Results
Recombinant human growth hormone had no significant effect on systolic or diastolic cardiac function, exercise capacity or neuroendocrine activation. In addition, there was no overall improvement in functional class or dyspnoea grade. Insulin-like growth factor-I significantly increased demonstrating that the growth hormone had an endocrine effect.
Conclusion
This is the first double-blind and placebo-controlled study of the administration, over 3 months, of recombinant human growth hormone in patients with congestive heart failure of different aetiologies. The treatment was safe and without serious side effects. However, no beneficial effects on cardiac function or structure could be detected.The European Society of Cardiology
Key Words: Congestive heart failure • Doppler echocardiography • growth hormone • insulin-like growth factor-I • radionuclide angiography
f1 Correspondence: Kenneth Caidahl MD, PhD, Department of Clinical Physiology, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. P. Dunn, B. Bleske, M. Dorsch, T. Macaulay, B. Van Tassell, and O. Vardeny Nutrition and Heart Failure: Impact of Drug Therapies and Management Strategies Nutr Clin Pract, February 1, 2009; 24(1): 60 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bruel, T. E.H. Christoffersen, and J. R. Nyengaard Growth hormone increases the proliferation of existing cardiac myocytes and the total number of cardiac myocytes in the rat heart Cardiovasc Res, December 1, 2007; 76(3): 400 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fazio, E. A. Palmieri, F. Affuso, A. Cittadini, G. Castellano, T. Russo, A. Ruvolo, R. Napoli, and L. Sacca Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients with Chronic Heart Failure J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4218 - 4223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Ibe, A. Saraste, S. Lindemann, S. Bruder, M. Buerke, H. Darius, K. Pulkki, and L.-M. Voipio-Pulkki Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodelling in dilated cardiomyopathy, but is not affected by growth hormone treatment Eur J Heart Fail, February 1, 2007; 9(2): 160 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. von Haehling, W. Doehner, and S. D Anker Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure Cardiovasc Res, January 15, 2007; 73(2): 298 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Le Corvoisier, L. Hittinger, P. Chanson, O. Montagne, I. Macquin-Mavier, and P. Maison Cardiac Effects of Growth Hormone Treatment in Chronic Heart Failure: A Meta-Analysis J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 180 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Schwarz, P. Jammula, R. Gupta, and S. Rosanio A Case and Review of Acromegaly-Induced Cardiomyopathy and the Relationship Between Growth Hormone and Heart Failure: Cause or Cure or Neither or Both? Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2006; 11(4): 232 - 244. [Abstract] [PDF]
|
|
|
|
|
|
S. Marleau, M. Mulumba, D. Lamontagne, and H. Ong Cardiac and peripheral actions of growth hormone and its releasing peptides: Relevance for the treatment of cardiomyopathies Cardiovasc Res, January 1, 2006; 69(1): 26 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Lipshultz, S. A. Vlach, S. R. Lipsitz, S. E. Sallan, M. L. Schwartz, and S. D. Colan Cardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines Pediatrics, June 1, 2005; 115(6): 1613 - 1622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nagaya, J. Moriya, Y. Yasumura, M. Uematsu, F. Ono, W. Shimizu, K. Ueno, M. Kitakaze, K. Miyatake, and K. Kangawa Effects of Ghrelin Administration on Left Ventricular Function, Exercise Capacity, and Muscle Wasting in Patients With Chronic Heart Failure Circulation, December 14, 2004; 110(24): 3674 - 3679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tivesten, A. Barlind, K. Caidahl, N. Klintland, A. Cittadini, C. Ohlsson, and J. Isgaard Growth hormone-induced blood pressure decrease is associated with increased mRNA levels of the vascular smooth muscle KATP channel J. Endocrinol., October 1, 2004; 183(1): 195 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. McElhinney, S. D. Colan, A. M. Moran, D. Wypij, M. Lin, J. A. Majzoub, E. C. Crawford, J. M. Bartlett, E. A. McGrath, and J. W. Newburger Recombinant Human Growth Hormone Treatment for Dilated Cardiomyopathy in Children Pediatrics, October 1, 2004; 114(4): e452 - e458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Dalla Libera, B. Ravara, M. Volterrani, V. Gobbo, M. Della Barbera, A. Angelini, D. D. Betto, E. Germinario, and G. Vescovo Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure Am J Physiol Cell Physiol, January 1, 2004; 286(1): C138 - C144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Adamopoulos, J. T. Parissis, I. Paraskevaidis, D. Karatzas, E. Livanis, M. Georgiadis, G. Karavolias, D. Mitropoulos, D. Degiannis, and D. Th. Kremastinos Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy Eur. Heart J., December 2, 2003; 24(24): 2186 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Meyers and R. C. Cuneo Controversies Regarding the Effects of Growth Hormone on the Heart Mayo Clin. Proc., December 1, 2003; 78(12): 1521 - 1526. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Cittadini, J.o. Isgaard, M. G. Monti, C. Casaburi, A. Di Gianni, R. Serpico, G. Iaccarino, and L. Sacca Growth hormone prolongs survival in experimental postinfarction heart failure J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2154 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cittadini, L. Ines Comi, S. Longobardi, V. Rocco Petretta, C. Casaburi, L. Passamano, B. Merola, E. Durante-Mangoni, L. Sacca, and L. Politano A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies Eur. Heart J., April 1, 2003; 24(7): 664 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marleau, N. Lapointe, J. Massicotte, C. Cemeus, G. Jasmin, L. Dumont, M. G. Sirois, J.-L. Rouleau, P. du Souich, and H. Ong Effect of Chronic Treatment with Bovine Recombinant Growth Hormone on Cardiac Dysfunction and Lesion Progression in UM-X7.1 Cardiomyopathic Hamsters Endocrinology, December 1, 2002; 143(12): 4846 - 4855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colao, L. Spinelli, A. Cuocolo, S. Spiezia, R. Pivonello, C. di Somma, D. Bonaduce, M. Salvatore, and G. Lombardi Cardiovascular Consequences of Early-Onset Growth Hormone Excess J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3097 - 3104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Imazio, M. Bobbio, F. Broglio, A. Benso, V. Podio, M.R. Valetto, G. Bisi, E. Ghigo, and G.P. Trevi GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy Eur J Heart Fail, March 1, 2002; 4(2): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Pagel, T. Langenickel, K. Hohnel, S. Philipp, A. K. Nussler, W. F. Blum, M. L. Aubert, R. Dietz, and R. Willenbrock Cardiac and Renal Effects of Growth Hormone in Volume Overload-Induced Heart Failure: Role of NO Hypertension, January 1, 2002; 39(1): 57 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bollano, C.-H. Bergh, C. Kjellstrom, E. Omerovic, V. Kujacic, K. Caidahl, B.-A. Bengtsson, F. Waagstein, and J. Isgaard Growth hormone alone or combined with metoprolol preserves cardiac function after myocardial infarction in rats Eur J Heart Fail, December 1, 2001; 3(6): 651 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Cuneo GH and Cardiac Failure J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4635 - 4637. [Full Text] [PDF]
|
|
|
|
|
|
J. W. A. Smit, Y. J. H. Janssen, H. J. Lamb, E. E. van der Wall, M. P. M. Stokkel, E. Viergever, N. R. Biermasz, J. J. Bax, H. W. Vliegen, A. de Roos, et al. Six Months of Recombinant Human GH Therapy in Patients with Ischemic Cardiac Failure Does Not Influence Left Ventricular Function and Mass J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4638 - 4643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nagaya, M. Uematsu, M. Kojima, Y. Ikeda, F. Yoshihara, W. Shimizu, H. Hosoda, Y. Hirota, H. Ishida, H. Mori, et al. Chronic Administration of Ghrelin Improves Left Ventricular Dysfunction and Attenuates Development of Cardiac Cachexia in Rats With Heart Failure Circulation, September 18, 2001; 104(12): 1430 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Anker, M. Volterrani, C.-D. Pflaum, C. J. Strasburger, K. J. Osterziel, W. Doehner, M. B. Ranke, P. A. Poole-Wilson, A. Giustina, R. Dietz, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone J. Am. Coll. Cardiol., August 1, 2001; 38(2): 443 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Akner and T. Cederholm Treatment of protein-energy malnutrition in chronic nonmalignant disorders Am. J. Clinical Nutrition, July 1, 2001; 74(1): 6 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Weekers, E. Van Herck, J. Isgaard, and G. Van den Berghe Pretreatment with Growth Hormone-Releasing Peptide-2 Directly Protects against the Diastolic Dysfunction of Myocardial Stunning in an Isolated, Blood-Perfused Rabbit Heart Model Endocrinology, November 1, 2000; 141(11): 3993 - 3999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Kotler Cachexia Ann Intern Med, October 17, 2000; 133(8): 622 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E. Botker, H. Wiggers, M. Bottcher, J. S. Christiansen, T. T. Nielsen, A. Gjedde, and O. Schmitz Short-term effects of growth hormone on myocardial glucose uptake in healthy humans Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E1053 - E1059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Osterziel, W. F. Blum, O. Strohm, and R. Dietz The Severity of Chronic Heart Failure due to Coronary Artery Disease Predicts the Endocrine Effects of Short- Term Growth Hormone Administration J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1533 - 1539. [Abstract] [Full Text]
|
|
|
|
|
|
S. D. Anker and M. Rauchhaus Heart failure as a metabolic problem Eur J Heart Fail, June 1, 1999; 1(2): 127 - 131. [Abstract] [Full Text] [PDF]
|
|